The latest market report published by Acute Market Reports “Global Listeria monocytogenes Infections Treatment Market - Growth, Share, Opportunities, Pipeline Analysis, Competitive Analysis, and Forecast, 2016 - 2023,” the Listeria monocytogenes infections treatment market was valued at USD 3,624.9 Mn in 2015, and is expected to reach USD 5,056.3 Mn by 2023, expanding at a CAGR of 4.74% from 2016 to 2023.
Browse the full report Listeria monocytogenes Infections Treatment Market - Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016 – 2023 at https://www.acutemarketreports.com/report/listeria-monocytogenes-infections-treatment-market
Market Insights
Listeria monocytogenes, is an important pathogen in pregnant patients, neonates, elderly individuals, and immunocompromised individuals, although an uncommon cause of illness in the general population. Listeria monocytogenes is a bacterial pathogen capable of causing severe infections in humans, often with fatal outcomes. According to USFDA, published studies suggest that 1- 8% of humans may be intestinal carriers of Listeria. According to Unites States Department of Agriculture (USDA), Listeria causes about 280 cases of illness in newborns in a typical year, resulting in 60 deaths and stillbirths. Infants can be infected before birth, and this infection can cause serious disability in newborns. About 35 infants are disabled as a result of infection from Listeria each year. The key factors assisting the growth of Listeria monocytogenes infections treatment market are rise in prevalence of foodborne diseases, stringent laws and policies issued by FDA, rising demand for healthy and microbial-free food, and high public awareness related to foodborne diseases in developed countries.
Pipeline Analysis
The phase III drugs included in the pipeline analysis are Carbavance (The Medicines Company), Telavancin (Theravance Biopharma Antibiotics, Inc.), Daptomycin (Merck & Co.), Prulifloxacin (Merck & Co.), and DTaP-IPV/Hib combined vaccine (Sanofi S.A.). According to market experts, the diversity of the several molecule types in the biologic group shows a certain level of innovation, with newer avenues being explored in accounts of recent failures. Overall, late stage clinical trials have highlighted very few molecules that could potentially replace current treatments during the forecast period.
Key Market Movements
